Previous 10 | Next 10 |
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions, has announced that its CEO Dr. David Young will present at the World Orphan Drug Congress US...
HANOVER, MD., July 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions announced to...
Gainers: Leju Holdings Limited (LEJU) +47%. Redbox Entertainment (RDBX) +33%. SIGA Technologies (SIGA) +26%. Getnet (GET) +25%. Allarity (ALLR) +23%. NanoViricides (NNVC) +22%. Processa Pharmaceuticals (PCSA) +22%. TherapeuticsMD (TXMD) +17%. PyroGenesis Canada (PYR) +17%. Evofem Biosciences ...
Processa Pharmaceuticals, Inc. (PCSA) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jim Stanker – Chief Financial Officer David Young – Chief Executive Officer Conference Call Participants Robin Garner – Craig-Hallum Naz Rahman – Max...
The following slide deck was published by Processa Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Processa Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, is reporting its financial results for the quarter ended Ma...
Processa Pharmaceuticals press release (NASDAQ:PCSA): Non-GAAP EPS of -$0.20. Cash balance of $14.4M at Mar. 31. Shares +1.03%. For further details see: Processa Pharmaceuticals Non-GAAP EPS of -$0.20
Amended Next Generation C apecitabine study has restarted which will elucidate timelines for de novo formation of DPD Expanded efforts for enrollment in PCS499 PCS12852 on target to complete enrollment by Q3 HANOVER, Md., May 12, 2022 (GLOBE NEWSW...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on May 12, 2022...
HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a con...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...